Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Ascendis Pharma announced that it will present Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) at the ISDS 2026 meeting. The data show durable improvements in growth and multiple physical functioning parameters in children with achondroplasia, alongside a safety profile similar to placebo. The FDA has appro…